An aqueous solvent composition is provided, comprising a nucleophilic component having one or more sterically unhindered primary or secondary amine moieties, a Brønsted base component having one or more basic nitrogen moieties, a water-soluble organic solvent, and water. A biphasic composition is provided, comprising one or more carbamate compounds, one or more conjugate acids of Brønsted base, a water-soluble organic solvent, and water. A biphasic CO.sub.2 absorption process is also provided, utilizing the biphasic solvent composition.

An aqueous solvent composition is provided, comprising a nucleophilic component having one or more sterically unhindered primary or secondary amine moieties, a Brønsted base component having one or more basic nitrogen moieties, a water-soluble organic solvent, and water. A biphasic composition is provided, comprising one or more carbamate compounds, one or more conjugate acids of Brønsted base, a water-soluble organic solvent, and water. A biphasic CO.sub.2 absorption process is also provided, utilizing the biphasic solvent composition.

Present invention relates to the protection of peptides and proteins against aggregation.

The process and compositions according to the invention improve protein stability in presence of cyclodextrins without establishing any covalent interactions, only by inclusion and/or electrostatic phenomena. The carbohydrate compositions provide a temporary local molecular coating on the surface of protein macromolecules, via physical glycosylation.

Present invention relates to the protection of peptides and proteins against aggregation.

The process and compositions according to the invention improve protein stability in presence of cyclodextrins without establishing any covalent interactions, only by inclusion and/or electrostatic phenomena. The carbohydrate compositions provide a temporary local molecular coating on the surface of protein macromolecules, via physical glycosylation.

The present disclosure provides compositions, methods, and devices for sensing, detecting, and/or selectively capturing phosphate from water. An exemplary method includes: contacting a ligand or a rare earth metal complex of a ligand as described herein with an aqueous phosphate-containing medium at a pH of 5 to 12 under conditions sufficient to bind phosphate (e.g., reversibly bind phosphate). In certain embodiments, the method further includes releasing the bound phosphate by contacting the bound phosphate complex with an aqueous medium at a pH of 0 to 4 under conditions sufficient to release the bound phosphate.

The present disclosure provides compositions, methods, and devices for sensing, detecting, and/or selectively capturing phosphate from water. An exemplary method includes: contacting a ligand or a rare earth metal complex of a ligand as described herein with an aqueous phosphate-containing medium at a pH of 5 to 12 under conditions sufficient to bind phosphate (e.g., reversibly bind phosphate). In certain embodiments, the method further includes releasing the bound phosphate by contacting the bound phosphate complex with an aqueous medium at a pH of 0 to 4 under conditions sufficient to release the bound phosphate.

A method is provided for collecting a compound of formula (III) (in which R31 is a monovalent to trivalent organic group and n31 is an integer of 1 to 3) from a liquid phase component that is formed as a by-product in a method for producing a compound of general formula (I) (in which R11 is a monovalent to trivalent organic group and n 11 is an integer of 1 to 3), wherein the collection method contains steps (1) to (3) or steps (A) and (B), and step (4). Step (1): a step for reacting the liquid phase component with at least one active hydrogen-containing compound in a reactor. Step (2): a step for returning a condensed liquid obtained by cooling gas phase components in the reactor to the reactor. Step (3): a step for discharging gas phase components that are not condensed in the step (2) to the outside of the reactor. Step (A): a step for mixing the liquid phase component, water, and a compound of general formula (III). Step (B): a step for reacting the liquid phase component with water inside the reactor. Step (4): a step for discharging, as a liquid phase component inside the reactor, the reaction liquid containing the compound of general formula (III) to the outside of the reactor.

R.sup.11NCO).sub.n11  (I)

R.sup.31NH.sub.2).sub.n31  (III)

A method is provided for collecting a compound of formula (III) (in which R31 is a monovalent to trivalent organic group and n31 is an integer of 1 to 3) from a liquid phase component that is formed as a by-product in a method for producing a compound of general formula (I) (in which R11 is a monovalent to trivalent organic group and n 11 is an integer of 1 to 3), wherein the collection method contains steps (1) to (3) or steps (A) and (B), and step (4). Step (1): a step for reacting the liquid phase component with at least one active hydrogen-containing compound in a reactor. Step (2): a step for returning a condensed liquid obtained by cooling gas phase components in the reactor to the reactor. Step (3): a step for discharging gas phase components that are not condensed in the step (2) to the outside of the reactor. Step (A): a step for mixing the liquid phase component, water, and a compound of general formula (III). Step (B): a step for reacting the liquid phase component with water inside the reactor. Step (4): a step for discharging, as a liquid phase component inside the reactor, the reaction liquid containing the compound of general formula (III) to the outside of the reactor.

R.sup.11NCO).sub.n11  (I)

R.sup.31NH.sub.2).sub.n31  (III)

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.